

Eric Hollander

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9190196/publications.pdf>

Version: 2024-02-01

126
papers

10,286
citations

38742

50
h-index

34986

98
g-index

128
all docs

128
docs citations

128
times ranked

7892
citing authors

#	ARTICLE	IF	CITATIONS
1	Oxytocin Infusion Reduces Repetitive Behaviors in Adults with Autistic and Asperger's Disorders. <i>Neuropsychopharmacology</i> , 2003, 28, 193-198.	5.4	632
2	Oxytocin Increases Retention of Social Cognition in Autism. <i>Biological Psychiatry</i> , 2007, 61, 498-503.	1.3	632
3	Probing Compulsive and Impulsive Behaviors, from Animal Models to Endophenotypes: A Narrative Review. <i>Neuropsychopharmacology</i> , 2010, 35, 591-604.	5.4	588
4	Lack of Efficacy of Citalopram in Children With Autism Spectrum Disorders and High Levels of Repetitive Behavior. <i>Archives of General Psychiatry</i> , 2009, 66, 583.	12.3	416
5	A Placebo Controlled Crossover Trial of Liquid Fluoxetine on Repetitive Behaviors in Childhood and Adolescent Autism. <i>Neuropsychopharmacology</i> , 2005, 30, 582-589.	5.4	364
6	Limbic Circuitry in Patients With Autism Spectrum Disorders Studied With Positron Emission Tomography and Magnetic Resonance Imaging. <i>American Journal of Psychiatry</i> , 2000, 157, 1994-2001.	7.2	354
7	Striatal Volume on Magnetic Resonance Imaging and Repetitive Behaviors in Autism. <i>Biological Psychiatry</i> , 2005, 58, 226-232.	1.3	352
8	Treatment non-response in OCD: methodological issues and operational definitions. <i>International Journal of Neuropsychopharmacology</i> , 2002, 5, 181-91.	2.1	325
9	Intranasal oxytocin versus placebo in the treatment of adults with autism spectrum disorders: a randomized controlled trial. <i>Molecular Autism</i> , 2012, 3, 16.	4.9	293
10	Clomipramine vs Desipramine Crossover Trial in Body Dysmorphic Disorder. <i>Archives of General Psychiatry</i> , 1999, 56, 1033.	12.3	256
11	Divalproex in the Treatment of Impulsive Aggression: Efficacy in Cluster B Personality Disorders. <i>Neuropsychopharmacology</i> , 2003, 28, 1186-1197.	5.4	231
12	Short-Term Single-Blind Fluvoxamine Treatment of Pathological Gambling. <i>American Journal of Psychiatry</i> , 1998, 155, 1781-1783.	7.2	216
13	Does Sustained-Release Lithium Reduce Impulsive Gambling and Affective Instability Versus Placebo in Pathological Gamblers With Bipolar Spectrum Disorders?. <i>American Journal of Psychiatry</i> , 2005, 162, 137-145.	7.2	191
14	An Open Trial of Divalproex Sodium in Autism Spectrum Disorders. <i>Journal of Clinical Psychiatry</i> , 2001, 62, 530-534.	2.2	187
15	Divalproex Sodium vs Placebo for the Treatment of Irritability in Children and Adolescents with Autism Spectrum Disorders. <i>Neuropsychopharmacology</i> , 2010, 35, 990-998.	5.4	179
16	Treating body dysmorphic disorder with medication: Evidence, misconceptions, and a suggested approach. <i>Body Image</i> , 2008, 5, 13-27.	4.3	174
17	ADouble-Blind Placebo-Controlled Pilot Study of Olanzapine in Childhood/Adolescent Pervasive Developmental Disorder. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2006, 16, 541-548.	1.3	171
18	A Double-Blind Placebo-Controlled Trial of Fluoxetine for Repetitive Behaviors and Global Severity in Adult Autism Spectrum Disorders. <i>American Journal of Psychiatry</i> , 2012, 169, 292-299.	7.2	169

#	ARTICLE	IF	CITATIONS
19	Impact of Trait Impulsivity and State Aggression on Divalproex Versus Placebo Response in Borderline Personality Disorder. <i>American Journal of Psychiatry</i> , 2005, 162, 621-624.	7.2	168
20	Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. <i>International Journal of Neuropsychopharmacology</i> , 2003, 6, 397-401.	2.1	166
21	Excitatory/inhibitory imbalance in autism spectrum disorders: Implications for interventions and therapeutics. <i>World Journal of Biological Psychiatry</i> , 2016, 17, 174-186.	2.6	148
22	Divalproex sodium vs. placebo in the treatment of repetitive behaviours in autism spectrum disorder. <i>International Journal of Neuropsychopharmacology</i> , 2006, 9, 209.	2.1	126
23	Autism and Oxytocin: New Developments in Translational Approaches to Therapeutics. <i>Neurotherapeutics</i> , 2010, 7, 250-257.	4.4	123
24	Obsessive-compulsive behaviors in parents of multiplex autism families. <i>Psychiatry Research</i> , 2003, 117, 11-16.	3.3	122
25	Lithium and Valproate Treatment of Pathological Gambling. <i>Journal of Clinical Psychiatry</i> , 2002, 63, 559-564.	2.2	122
26	Levetiracetam versus placebo in childhood and adolescent autism: a double-blind placebo-controlled study. <i>International Clinical Psychopharmacology</i> , 2006, 21, 363-367.	1.7	114
27	Symptom domains in autism and related conditions: Evidence for familiarity. <i>American Journal of Medical Genetics Part A</i> , 2002, 114, 64-73.	2.4	111
28	Acute and Long-Term Treatment and Prevention of Relapse of Obsessive-Compulsive Disorder With Paroxetine. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 1113-1121.	2.2	107
29	Comorbidity in obsessive-compulsive disorder (OCD): A report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS). <i>Comprehensive Psychiatry</i> , 2014, 55, 1513-1519.	3.1	105
30	The cost and impact of compulsivity: A research perspective. <i>European Neuropsychopharmacology</i> , 2016, 26, 800-809.	0.7	105
31	Effect of fluoxetine on regional cerebral metabolism in autistic spectrum disorders: a pilot study. <i>International Journal of Neuropsychopharmacology</i> , 2001, 4, 119-25.	2.1	100
32	Early intervention for obsessive compulsive disorder: An expert consensus statement. <i>European Neuropsychopharmacology</i> , 2019, 29, 549-565.	0.7	92
33	Should OCD leave the anxiety disorders in DSM-V? The case for obsessive compulsive-related disorders. <i>Depression and Anxiety</i> , 2008, 25, 317-329.	4.1	87
34	Compulsivity, impulsivity, and the DSM-5 process. <i>CNS Spectrums</i> , 2014, 19, 62-68.	1.2	86
35	Quality of Life Outcomes in Patients With Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 784-792.	2.2	82
36	Targeted treatments for symptom domains in child and adolescent autism. <i>Lancet</i> , The, 2003, 362, 732-734.	13.7	79

#	ARTICLE	IF	CITATIONS
37	PATHOLOGICAL GAMBLING. <i>Psychiatric Clinics of North America</i> , 2000, 23, 629-642.	1.3	78
38	The obsessive-compulsive spectrum disorders. <i>International Review of Psychiatry</i> , 1997, 9, 99-110.	2.8	76
39	A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Controlled-Release Fluvoxamine in Patients With Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 640-647.	2.2	73
40	Clinical advances in obsessive-compulsive disorder: a position statement by the International College of Obsessive-Compulsive Spectrum Disorders. <i>International Clinical Psychopharmacology</i> , 2020, 35, 173-193.	1.7	70
41	The Role of Ionotropic Glutamate Receptors in Childhood Neurodevelopmental Disorders: Autism Spectrum Disorders and Fragile X Syndrome. <i>Current Neuropharmacology</i> , 2014, 12, 71-98.	2.9	65
42	A Single Dose, Randomized, Controlled Proof-Of-Mechanism Study of a Novel Vasopressin 1a Receptor Antagonist (RG7713) in High-Functioning Adults with Autism Spectrum Disorder. <i>Neuropsychopharmacology</i> , 2017, 42, 1914-1923.	5.4	63
43	Antiepileptic Medications in Autism Spectrum Disorder: A Systematic Review and Meta-Analysis. <i>Journal of Autism and Developmental Disorders</i> , 2014, 44, 948-957.	2.7	62
44	A Double-Blind, Placebo-Controlled Trial of Clonazepam in Obsessive-Compulsive Disorder. <i>World Journal of Biological Psychiatry</i> , 2003, 4, 30-34.	2.6	61
45	Cross-cutting issues and future directions for the OCD spectrum. <i>Psychiatry Research</i> , 2009, 170, 3-6.	3.3	61
46	Association analysis of the NrCAM gene in autism and in subsets of families with severe obsessive-compulsive or self-stimulatory behaviors. <i>Psychiatric Genetics</i> , 2006, 16, 251-257.	1.1	60
47	Psychopharmacologic Interventions for Repetitive Behaviors in Autism Spectrum Disorders. <i>Child and Adolescent Psychiatric Clinics of North America</i> , 2008, 17, 753-771.	1.9	55
48	Effects of age and symptomatology on cortical thickness in autism spectrum disorders. <i>Research in Autism Spectrum Disorders</i> , 2013, 7, 141-150.	1.5	55
49	Pharmacological treatment strategies in obsessive compulsive disorder: A cross-sectional view in nine international OCD centers. <i>Journal of Psychopharmacology</i> , 2014, 28, 596-602.	4.0	55
50	Pharmacological Treatments of Pathological Gambling. <i>Journal of Gambling Studies</i> , 2005, 21, 99-108.	1.6	53
51	Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder. <i>International Clinical Psychopharmacology</i> , 2006, 21, 189-191.	1.7	53
52	The influence of age at onset and duration of illness on long-term outcome in patients with obsessive-compulsive disorder: A report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). <i>European Neuropsychopharmacology</i> , 2013, 23, 865-871.	0.7	53
53	Imaging monetary reward in pathological gamblers. <i>World Journal of Biological Psychiatry</i> , 2005, 6, 113-120.	2.6	52
54	Autism-related routines and rituals associated with a mitochondrial aspartate/glutamate carrier SLC25A12 polymorphism. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2008, 147B, 408-410.	1.7	51

#	ARTICLE	IF	CITATIONS
55	Venlafaxine in Treatment-Resistant Obsessive-Compulsive Disorder. <i>Journal of Clinical Psychiatry</i> , 2003, 64, 546-550.	2.2	51
56	Childhood, adolescent and adult age at onset and related clinical correlates in obsessive-compulsive disorder: a report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCs). <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 210-217.	2.4	50
57	Baseline Factors Predicting Placebo Response to Treatment in Children and Adolescents With Autism Spectrum Disorders. <i>JAMA Pediatrics</i> , 2013, 167, 1045.	6.2	49
58	Lack of Evidence for Association of the Serotonin Transporter Gene SLC6A4 with Autism. <i>Biological Psychiatry</i> , 2006, 60, 186-191.	1.3	48
59	Hypothalamic-pituitary-adrenal Axis Dysregulation in Depersonalization Disorder. <i>Neuropsychopharmacology</i> , 2001, 25, 793-795.	5.4	47
60	Obsessive-compulsive disorder and spectrum across the life span. <i>International Journal of Psychiatry in Clinical Practice</i> , 2005, 9, 79-86.	2.4	46
61	FDG-PET Study in Pathological Gamblers. <i>Neuropsychobiology</i> , 2008, 58, 37-47.	1.9	45
62	An expert opinion on PANDAS/PANS: highlights and controversies. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 91-98.	2.4	43
63	SSRIs in the Treatment of obsessive-compulsive disorder. <i>Depression and Anxiety</i> , 1998, 8, 105-113.	4.1	41
64	The 5-HT 2A receptor and serotonin transporter in Asperger's Disorder: A PET study with [11 C]MDL 100907 and [11 C]DASB. <i>Psychiatry Research - Neuroimaging</i> , 2011, 194, 230-234.	1.8	41
65	An Open-Label Trial of Venlafaxine in Body Dysmorphic Disorder. <i>CNS Spectrums</i> , 2008, 13, 138-144.	1.2	40
66	Diagnosis and treatment of pathologic gambling. <i>Current Psychiatry Reports</i> , 2003, 5, 9-15.	4.5	38
67	Psychosocial Function and Economic Costs of Obsessive-Compulsive Disorder. <i>CNS Spectrums</i> , 1998, 3, 48-58.	1.2	34
68	Neurological Soft Signs as Predictors of Treatment Response to Selective Serotonin Reuptake Inhibitors in Obsessive-Compulsive Disorder. <i>Journal of Neuropsychiatry and Clinical Neurosciences</i> , 2005, 17, 472-477.	1.8	34
69	The Consequences of Compulsive Sexual Behavior: The Preliminary Reliability and Validity of the Compulsive Sexual Behavior Consequences Scale. <i>Sexual Addiction and Compulsivity</i> , 2007, 14, 207-220.	0.9	32
70	A Dimensional Approach to the Autism Spectrum. <i>CNS Spectrums</i> , 1998, 3, 22-39.	1.2	31
71	Better than treated as usual: Transcranial magnetic stimulation augmentation in selective serotonin reuptake inhibitor-refractory obsessive-compulsive disorder, mini-review and pilot open-label trial. <i>Journal of Psychopharmacology</i> , 2016, 30, 568-578.	4.0	30
72	Intranasal oxytocin versus placebo for hyperphagia and repetitive behaviors in children with Prader-Willi Syndrome: A randomized controlled pilot trial. <i>Journal of Psychiatric Research</i> , 2021, 137, 643-651.	3.1	29

#	ARTICLE	IF	CITATIONS
73	Management of Obsessive-Compulsive Disorder. F1000prime Reports, 2014, 6, 68.	5.9	28
74	Presentation and management of anxiety in individuals with acute symptomatic or asymptomatic COVID-19 infection, and in the post-COVID-19 recovery phase. International Journal of Psychiatry in Clinical Practice, 2021, 25, 115-131.	2.4	27
75	Body dysmorphic disorder: a treatment synthesis and consensus on behalf of the International College of Obsessive-Compulsive Spectrum Disorders and the Obsessive Compulsive and Related Disorders Network of the European College of Neuropsychopharmacology. International Clinical Psychopharmacology, 2021, 36, 61-75.	1.7	27
76	Neurological considerations: Autism and Parkinson's disease. Psychiatry Research, 2009, 170, 43-51.	3.3	25
77	NeuroCOVID-19: A clinical neuroscience-based approach to reduce SARS-CoV-2 related mental health sequelae. Journal of Psychiatric Research, 2020, 130, 215-217.	3.1	25
78	BODY DYSMORPHIC DISORDER. Psychiatric Clinics of North America, 2000, 23, 617-628.	1.3	24
79	Non-Paraphilic Compulsive Sexual Behavior and Psychiatric Co-morbidities in Gay and Bisexual Men. Sexual Addiction and Compulsivity, 2011, 18, 114-134.	0.9	24
80	Obsessive-compulsive spectrum disorders. Dialogues in Clinical Neuroscience, 2003, 5, 259-271.	3.7	24
81	Refractory obsessive-compulsive disorder: state-of-the-art treatment. Journal of Clinical Psychiatry, 2002, 63 Suppl 6, 20-9.	2.2	24
82	Balovaptan vs Placebo for Social Communication in Childhood Autism Spectrum Disorder. JAMA Psychiatry, 2022, 79, 760.	11.0	22
83	Sexual Dysfunction Associated with the Drug Treatment of Psychiatric Disorders. CNS Drugs, 1994, 2, 78-86.	5.9	20
84	Factor Analysis of Repetitive Behaviors in Autism as Measured by the Y-BOCS. Journal of Neuropsychiatry and Clinical Neurosciences, 2011, 23, 332-339.	1.8	20
85	From Treatment Response to Recovery: A Realistic Goal in OCD. International Journal of Neuropsychopharmacology, 2018, 21, 1007-1013.	2.1	20
86	Impact of Recent Findings on Study Design of Future Autism Clinical Trials. CNS Spectrums, 2004, 9, 49-56.	1.2	19
87	Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient Outcomes) trial. Journal of the Neurological Sciences, 2016, 365, 190-198.	0.6	19
88	Compulsivity in Alcohol Use Disorder and Obsessive Compulsive Disorder: Implications for Neuromodulation. Frontiers in Behavioral Neuroscience, 2019, 13, 70.	2.0	19
89	Diagnosis and treatment of body dysmorphic disorder in adolescents. Current Psychiatry Reports, 2002, 4, 108-113.	4.5	18
90	Fluvoxamine: a selective serotonin re-uptake inhibitor for the treatment of obsessive-compulsive disorder. Expert Opinion on Pharmacotherapy, 2005, 6, 2727-2740.	1.8	18

#	ARTICLE	IF	CITATIONS
91	rTMS in resistant mixed states: An exploratory study. <i>Journal of Affective Disorders</i> , 2014, 157, 66-71.	4.1	18
92	Cigarette smoking in patients with obsessive compulsive disorder: a report from the International College of Obsessive Compulsive Spectrum Disorders (ICOCS). <i>CNS Spectrums</i> , 2015, 20, 469-473.	1.2	18
93	Oxytocin and Prader-Willi Syndrome. <i>Current Topics in Behavioral Neurosciences</i> , 2017, 35, 529-557.	1.7	18
94	New treatment models for compulsive disorders. <i>European Neuropsychopharmacology</i> , 2016, 26, 877-884.	0.7	17
95	New perspectives in the treatment of body dysmorphic disorder. <i>F1000Research</i> , 2018, 7, 361.	1.6	16
96	Pharmacological Treatment of Body Dysmorphic Disorder. <i>Current Neuropharmacology</i> , 2019, 17, 697-702.	2.9	14
97	Randomized crossover feasibility trial of helminthic <i>Trichuris suis</i> ova versus placebo for repetitive behaviors in adult autism spectrum disorder. <i>World Journal of Biological Psychiatry</i> , 2020, 21, 291-299.	2.6	13
98	Standards of care for obsessive-compulsive disorder centres. <i>International Journal of Psychiatry in Clinical Practice</i> , 2016, 20, 204-208.	2.4	12
99	Body Dysmorphic Disorder in Patients With Autism Spectrum Disorder: A Reflection of Increased Local Processing and Self-Focus. <i>American Journal of Psychiatry</i> , 2017, 174, 313-316.	7.2	12
100	Clinical features associated with increased severity of illness in tertiary clinic referred patients with obsessive compulsive disorder. <i>International Journal of Psychiatry in Clinical Practice</i> , 2017, 21, 131-136.	2.4	12
101	Obsessive-Compulsive Spectrum Disorders: A Review. , 2001, , 203-252.		10
102	Are there new advances in the pharmacotherapy of autism spectrum disorders?. <i>World Psychiatry</i> , 2017, 16, 101-102.	10.4	10
103	Large multicenter randomized trials in autism: key insights gained from the balovaptan clinical development program. <i>Molecular Autism</i> , 2022, 13, .	4.9	10
104	Clinical characteristics and comorbidity associated with female gender in obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2020, 131, 209-214.	3.1	9
105	The role of gender in a large international OCD sample: A Report from the International College of Obsessive-Compulsive Spectrum Disorders (ICOCS) Network. <i>Comprehensive Psychiatry</i> , 2022, 116, 152315.	3.1	9
106	Pharmacotherapy in body dysmorphic disorder: relapse prevention and novel treatments. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 1211-1219.	1.8	8
107	Potential of cannabinoids as treatments for autism spectrum disorders. <i>Journal of Psychiatric Research</i> , 2021, 137, 194-201.	3.1	8
108	Social Synchrony and Oxytocin: From Behavior to Genes to Therapeutics. <i>American Journal of Psychiatry</i> , 2013, 170, 1086-1089.	7.2	7

#	ARTICLE	IF	CITATIONS
109	Modulating neuroinflammation in COVID-19 patients with obsessive-compulsive disorder. <i>Journal of Psychiatric Research</i> , 2022, 149, 367-373.	3.1	7
110	Obsessive-Compulsive Spectrum Disorders: A Review. , 2003, , 203-252.		6
111	Anxiety and OC spectrum disorders over life cycle. <i>International Journal of Psychiatry in Clinical Practice</i> , 2007, 11, 5-10.	2.4	6
112	Pathological gambling treated with lithium: The role of assessing temperament. <i>Addictive Behaviors</i> , 2014, 39, 1911-1913.	3.0	6
113	Catalysts for Change: The Role of Small Business Funders in the Creation and Dissemination of Innovation. <i>Journal of Autism and Developmental Disorders</i> , 2015, 45, 3900-3904.	2.7	6
114	SSRIs in the Treatment of obsessive-compulsive disorder. <i>Depression and Anxiety</i> , 1998, 8, 105-113.	4.1	6
115	Compulsivity and impulsivity—personal reflections: why now and why here?. <i>CNS Spectrums</i> , 2014, 19, 6-7.	1.2	4
116	Mesenchymal stem cells in autism spectrum and neurodevelopmental disorders: pitfalls and potential promises. <i>World Journal of Biological Psychiatry</i> , 2015, 16, 368-375.	2.6	4
117	Psychotropic Treatment of Autism. <i>Key Issues in Mental Health</i> , 0, , 151-165.	0.6	3
118	Beyond refractory obsessions and anxiety states: toward remission. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 14, 3-5.	2.2	3
119	Liquid Fluoxetine versus Placebo for Repetitive Behaviors in Childhood Autism. <i>Progress in Neurotherapeutics and Neuropsychopharmacology</i> , 2006, 1, 105-113.	0.0	2
120	The Montefiore-Einstein Rigidity Scale-Revised (MERS-R): Development, administration, reliability, and validity in child and adult Autism Spectrum Disorder (ASD). <i>Journal of Psychiatric Research</i> , 2022, 147, 142-147.	3.1	2
121	Liquid fluoxetine versus placebo for repetitive behaviors in childhood autism. , 0, , 105-114.		1
122	Behavioral phenotype in a child with Prader-Willi syndrome and comorbid 47, XYY. <i>Intractable and Rare Diseases Research</i> , 2016, 5, 235-237.	0.9	1
123	Citalopram Did Not Significantly Improve Anxiety in Children with Autism Spectrum Disorder Undergoing Treatment for Core Symptoms: Secondary Analysis of a Trial to Reduce Repetitive Behaviors. <i>Journal of Child and Adolescent Psychopharmacology</i> , 2022, 32, 233-241.	1.3	1
124	Psychobiology of Impulse-Control Disorders Not Otherwise Specified (NOS). , 0, , 1315-1329.		0
125	Challenges in assessing change in autistic adults: scale limitations and discrepancies in reporting in clinical trials. <i>International Journal of Psychiatry in Clinical Practice</i> , 2021, , 1-5.	2.4	0
126	Commentary on the article: “Maintenance of wellness in patients with obsessive-compulsive disorder who discontinue medication after exposure/response prevention augmentation A randomized clinical trial” Foa EB et al., <i>JAMA Psychiatry</i> . 2022;79(3):193-200 (1). <i>Comprehensive Psychiatry</i> , 2022, 116, 152323.	3.1	0